ONCOGENEX PHARMACEUTICALS, INC. (NASDAQ:OGXI) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
On February23, 2017, OncoGenex Pharmaceuticals, Inc. (the
Company) issued a press release announcing its financial results
for the fourth quarter and year ended December31, 2016. A copy of
the press release is furnished as Exhibit99.1 to this Current
Report on Form8-K.
| Item9.01. | Financial Statements and Exhibits. |
(d)
Exhibits
|
ExhibitNo. |
Description |
|
| 99.1 |
Press release of OncoGenex Pharmaceuticals, Inc. dated February23, 2017 |
The information in
Item2.02 of this Form 8-K and Exhibit 99.1 attached hereto is
furnished and shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), nor shall it be deemed incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in such filing.
Important
Additional Information about the Proposed Merger
This communication
is being made in respect of the proposed merger
involvingOncoGenex Pharmaceuticals, Inc.andAchieve Life Science,
Inc.OncoGenex intends to file a registration statement on Form
S-4 with theSEC, which will contain a joint proxy
statement/prospectus and other relevant materials, and plans to
file with theSECother documents regarding the proposed
transaction. The final joint proxy statement/prospectus will be
sent to the stockholders of OncoGenex and Achieve. The joint
proxy statement/prospectus will contain information about
OncoGenex, Achieve, the proposed merger and related matters.
STOCKHOLDERS ARE URGED TO READ THE JOINT PROXY
STATEMENT/PROSPECTUS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS)
AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR
ENTIRETY WHEN THEY BECOME AVAILABLE, AS THEY WILL CONTAIN
IMPORTANT INFORMATION THAT STOCKHOLDERS SHOULD CONSIDER BEFORE
MAKING A DECISION ABOUT THE MERGER AND RELATED
MATTERS.In addition to receiving the joint proxy
statement/prospectus and proxy card by mail, stockholders will
also be able to obtain the joint proxy statement/prospectus, as
well as other filings containing information about OncoGenex,
without charge, from theSECswebsite (http://www.sec.gov) or,
without charge, by directing a written request to:OncoGenex
Pharmaceuticals, Inc.,19820 North Creek Parkway,Suite
201,Bothell, WA98011, Attention: Investor Relations or toAchieve
Life Science, Inc.,30 Sunnyside Avenue,Mill Valley, CA94941,
Attention:Rick Stewart.
This
communication shall not constitute an offer to sell or the
solicitation of an offer to sell or the solicitation of an offer
to buy any securities, nor shall there be any sale of securities
in any jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under
the securities laws of any such jurisdiction. No offering of
securities in connection with the proposed merger shall be made
except by means of a prospectus meeting the requirements of
Section10 of the Securities Act of 1933, as amended.
Participants in
Solicitation
OncoGenex and its
executive officers and directors may be deemed to be participants
in the solicitation of proxies from OncoGenexs stockholders with
respect to the matters relating to the proposed merger. Achieve
and its officers and directors may also be deemed a participant
in such solicitation. Information regarding OncoGenexs executive
officers and directors is available in OncoGenexs proxy statement
on Schedule 14A, filed with theSEConApril 21, 2016. Information
regarding any interest that OncoGenex, Achieve or any of the
executive officers or directors of OncoGenex or Achieve may have
in the transaction with Achieve will be set forth in the joint
proxy statement/prospectus that OncoGenex intends to file with
theSECin connection with its stockholder vote on matters relating
to the proposed merger. Stockholders will be able to obtain this
information by reading the joint proxy statement/prospectus when
it becomes available.
About ONCOGENEX PHARMACEUTICALS, INC. (NASDAQ:OGXI)
OncoGenex Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company’s product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell’s adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27). OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins-2 and -5 (IGFBP-2, IGFBP-5). ONCOGENEX PHARMACEUTICALS, INC. (NASDAQ:OGXI) Recent Trading Information
ONCOGENEX PHARMACEUTICALS, INC. (NASDAQ:OGXI) closed its last trading session down -0.060 at 0.570 with 272,067 shares trading hands.
